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Abstract
Background: Fibrosis, the excessive deposition of scar tissue by fibroblasts, is one of the largest groups of diseases for
which there is no therapy. Fibroblasts from lesional areas of scleroderma patients possess elevated abilities to contract
matrix and produce a2smooth muscle actin (a-SMA), type I collagen and CCN2 (connective tissue growth factor, CTGF). The
basis for this phenomenon is poorly understood, and is a necessary prerequisite for developing novel, rational anti-fibrotic
strategies.
Methods and Findings: Compared to healthy skin fibroblasts, dermal fibroblasts cultured from lesional areas of scleroderma
(SSc) patients possess elevated Rac activity. NSC23766, a Rac inhibitor, suppressed the persistent fibrotic phenotype of
lesional SSc fibroblasts. NSC23766 caused a decrease in migration on and contraction of matrix, and a2SMA, type I collagen
and CCN2 mRNA and protein expression. SSc fibroblasts possessed elevated Akt phosphorylation, which was also blocked
by NSC23766. Overexpression of rac1 in normal fibroblasts induced matrix contraction and a2SMA, type I collagen and
CCN2 mRNA and protein expression. Rac1 activity was blocked by PI3kinase/Akt inhibition. Basal fibroblast activity was not
affected by NSC23766.
Conclusion: Rac inhibition may be considered as a novel treatment for the fibrosis observed in SSc.
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Introduction
Fibrosis is characterized by excessive deposition of scar tissue.
Fibrosis is one of the largest groups of diseases for which there is no
therapy. It has been estimated that nearly 45% of all deaths in the
developed world are caused fibrotic conditions which include:
cardiovascular disease, pulmonary fibrosis, diabetic nephropathy
and liver cirrhosis [1]. An example of a chronic fibrotic disease is
systemic sclerosis (SSc, scleroderma) which, in its diffuse form, can
affect the skin and internal organs such as the lung and kidney,
resulting in significant morbidity [2]. Although the fundamental
cause for fibrotic conditions including SSc is unclear, a common
theme of these diseases is the abnormal persistence of a particular
specialized form of fibroblast, termed the myofibroblast [3–5]. The
myofibroblast expresses a highly contractile form of actin, a-
smooth muscle actin (a2SMA) which is connected to the
extracellular matrix (ECM) through specialized cell surface
structured called focal adhesions (FAs) [3,4]. Thus, the myofibro-
blasts can exert mechanical tension on the ECM [6–8]. The
myofibroblast is considered to be responsible for the excessive
production, adhesion and contraction of ECM characterizing
fibrotic lesions [6,7].
Several different cytokines and extracellular proteins have been
identified that contribute to myofibroblast formation [e.g.,
transforming growth factor b (TGFb) endothelin-1, platelet
derived growth factor, Angiotensin, connective tissue growth
factor(CTGF, CCN2)] [9–13]. Considering SSc, studies using
specific inhibitors of individual cytokines inhibitors have been
found to be partially effective at alleviating the persistent fibrotic
phenotype of fibrotic fibroblasts; moreover, individual cytokines
appear to be responsible for complementary, overlapping features
of SSc fibroblasts [14–17]. Thus, additional strategies may be
warranted.
It is now appreciated that FA proteins can serve as a point of
convergence for signals emanating from stimulated growth factor
receptors [8,18]. As a specific example, the FA protein paxillin can
bind focal adhesion kinase (FAK) [19], and is responsible for the
recruitment of Rac1, a member of the Rho family of small
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migration both in vitro and in vivo [23–26]. We have shown that
mice possessing a fibroblast-specific deletion of Rac1 exhibit
impaired myofibroblast formation and function, associated with
delayed cutaneous tissue repair and resistance to bleomycin-
induced fibrosis [26,27].
The results described above strongly indicate that targeting
myofibroblast action by pharmacological inhibition of Rac may
represent a novel approach to inhibiting fibrosis. Dermal fibroblasts
cultured from lesional areas of SSc patients retain their fibrotic
phenotype for several passages in culture [5,28,29]. In this report,
we test the hypothesis that inhibition of Rac may reverse the
persistent fibrotic phenotype of fibroblasts cultured from lesional
areas of scleroderma patients. Our data provide new and valuable
insights into the fundamental basis of the fibrotic phenotype of SSc
fibroblasts and suggest a possible new course of therapy for SSc.
Methods
Cell culture, transfection and Western analysis
Dermalfibroblastswere isolated fromby explant culture of 4 mm
punch biopsies from the forearm of healthy individuals and those
with diffuse cutaneous scleroderma (6 each) in DMEM, 10% fetal
bovine serum (Invitrogen) as previously described [4,28]. Donors
were age-, site- and sex-matched. Experimental protocols were
approved by the Ethics Committee of the Royal Free Hospital
where all participants were recruited, under informed written
consent, and human experimentation was conducted. Cells (,80%
confluence) were serum-starved overnight, lysed in 2% SDS, and
proteins quantified(Pierce) andsubjectedto Westernblot analysis as
previously described [5,21]. Antibodies used were: phospho-Akt,
Akt (Cell Signaling), type I collagen (Biodesign), GAPDH (Sigma)
and secondary antibodies were from Abcam. Alternatively, RNA
was harvested using Trizol as described by the manufacturer
(Invitrogen). When indicated, cells were transfected (Fugene) with
empty expression vector or expression vector encoding active rac1
(courtesy Alan Hall, University College London) in a ratio of 2 mg
DNA:3 ml Fugene as described by the manufacturer and previously
[21]. Mouse fibroblasts deleted (K/K) or not (C/C) for rac1 were
previously generated and were cultured as previously described
[27].When indicated,cellsweretreatedwithDMSO (vehicle)orthe
rac inhibitor NSC23766 (50 mM in DMSO; Calbiochem), a rac-
specific small molecule which specifically binds to rac proteins and
prevents their activation at this concentration in fibroblasts [30,31].
Real time polymerase chain reaction (RT-PCR)
Dermal fibroblasts were serum-starved for 18 h and treated in
the presence or absence of 10 mM bosentan for 24 h. Total RNA
was isolated using Trizol (Invitrogen), and the integrity of the RNA
was verified by gel electrophoresis. Total RNA (10 mg) was reverse
transcribed in a 20-ml reaction volume containing an oligonucle-
otide (dT18) and random decamers (dN10) using M-MLV reverse
transcriptase (Promega) for 1 h at 37uC. Primers for SMA, Col1A2,
CTGF and Vinculin were as previously described [32, 33]. The
cDNA was diluted to 100 ml with diethylpyrocarbonate-treated
water, and the target was measured by real-time PCR FastStart
DNA Master SYBR Green (Roche Applied Science) according to
the manufacturer’s instructions. Triplicate samples were run,
transcripts were measured in picograms, and expression values
were standardized to values obtained with control 28S RNA.
Alternatively, total RNA (25 ng) was reverse transcribed and
amplified using TaqMan Assays on Demand (Applied Biosystems)
in a 15-ml reaction volume containing two unlabeled primers and
6-carboxyfluoroscein labeled TaqMan MGB probe. Samples were
combined with TaqMan one-step mastermix (Applied Biosystems).
Amplified sequences were detected using the ABI Prism 7900 HT
sequence detector (Perkin-Elmer-Cetus, Vaudreuil, QC) according
to the manufacturer’s instructions. Triplicate samples were run, and
expression values were standardized to values obtained with control
28 S RNA primers.
Collagen gel contraction
Experiments were performed essentially as described previously
[34]. Briefly, 24-well tissue culture plates were pre-coated with BSA.
Cells were used at passage 3. Trypsinized fibroblasts were suspended
in MCDB medium (Sigma) and mixed with collagen solution (one
part of 0.2 M N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
[HEPES], pH 8.0; four parts collagen [Vitrogen-100, 3 mg/ml] and
five parts of MCDB X 2) yielding a final concentration of 80,000 cells
per ml and 1.2 mg/ml collagen. Collagen/cell suspension (1 ml) was
added to each well. After polymerization, gels were detached from
wells by adding 1 ml of MCDB medium. Contraction of the gel was
quantified by measuring changes in gel weight, which is routinely used
as a measurement of gel contraction [34]; the weight arises due to the
media absorbed into the collagen gel. In parallel, gel contraction was
measured bycalculating the diameter of the contracted gel; results were
identical to those obtained when gel weight was measured.
Fibroblast populated collagen lattice (FPCL) contraction
assay
Measurement of contractile forces generated in a tethered,
floating fibroblast-populated collagen lattice (FPCL) was performed
as described [34,35]. Cells (1610
6 cells/ml) were seeded into a
collagen gel (First Link), floated in DMEM, 2% FBS, and forces
generated across the collagen lattice were measured over a 24 hour
period. Graphical readings are produced every 15 seconds
providing continuous measurements of generated forces (Dynes:
1610
25 N) [13,14], which are logged into a personal computer.
Migration assays
Cultured fibroblasts were cultured in 12-well plates. When cells
were confluent, medium was removed, cells were rinsed with
serum-free medium + 0.1% BSA and cultured for an additional
24 h in serum-free medium + 0.1% BSA. A uniform scratch was
them made across the plate with a blue pipette tip. Cells were
washed two times in PBS, and cultured in serum-free medium in
the presence of mitomycin C (10 mg/ml, Sigma).
Rac activity assay
A rac-GTP pulldown assay was used, essentially as previously
described (36; Upstate Biotechnology; Lake Placid, NY). Briefly,
fibroblasts were grown in 60 mm dishes and protein was harvested by
lysis in buffer containing NP-40. Agarose beads to which a PAK-GSH
fusion protein was conjugated was added and active Rac (Rac-GTP),
which binds PAK-GSH, was recovered through repeated centrifuga-
tion and washing of the agarose beads. Bound Rac was identified by
boiling beads in Laemmli buffer, and subjecting the resultant extracts
to SDS-PAGE and Western blot analysis using anti-Rac antibody.
When indicated, cell lysates were stimulated with GTPcS (100 mmol/
L) as a control to establish maximal Rac activation.
Results
The Rac inhibitor NSC23766 reduces the overexpression
of pro-fibrotic genes in SSc fibroblasts
To extend our previous data showing that rac1 was required for
bleomycin-induced skin fibrosis [26], we first used a standard,
Rac in Scleroderma
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was elevated in SSc dermal fibroblasts compared to control
fibroblasts (Figure 1). Conversely, rac expression was not altered
in SSc fibroblasts (Figure 1). To begin to assess whether heightened
rac activity contributed to the enhanced fibrotic phenotype of
lesional SSc fibroblasts, we used real-time PCR analysis to show, as
expected, that a-SMA, type I collagen (COL1A2), vinculin and
CTGF mRNAs were elevated in SSc dermal fibroblasts (SScF)
comparedtocontrolfibroblasts(NF) (Figure2A).Cellsincubatedfor
24 hours with the rac- specific inhibitor NSC23766 (50 mM)
showed reduced a-SMA, type I collagen (COL1A2), vinculin and
CTGF mRNA expression (Figure 2A). NSC23766 did not
appreciably affect mRNA expression in normal fibroblasts
(Figure 2A). Similar results were obtained when protein expression
was assessed using Western blot analysis; NSC23766 reduced
a2SMA, type I collagen, vinculin and CTGF protein expression in
SSc fibroblasts (Figure 2B). Consistent with these data, NSC23766
was able to reduce the appearance of a-SMA-containing stress
fibers in SSc fibroblasts (Figure 2C). These results are consistent
withthe notion that enhanced racactivity by lesional SScfibroblasts
contributes to the fibrotic phenotype of lesional SSc fibroblasts.
The Rac inhibitor NSC23766 reduces the enhanced ability
of lesional SSc fibroblasts to contract a collagen gel
matrix
To provide a functional context for our experiments, we then
assessed whether rac inhibition could alleviate the elevated ability
of lesional SSc fibroblasts to contract a collagen gel matrix. First,
we showed, as expected, that lesional SSc fibroblasts, relative to
control dermal fibroblasts, showed an enhanced ability to contract
a floating collagen gel matrix (Figure 3A) and to generate
contractile forces across a fibroblast populated collagen gel lattice
which was fixed at one end (Figure 3B). NSC23766 (24 hours;
50 mM) inhibited the enhanced ability of SSc fibroblasts to
contract a floating collagen gel, as well as exert contractile forces
across a collagen gel matrix (Figure 3A,B). These results provide
further support to the hypothesis that enhanced rac activity by
lesional SSc fibroblasts contributes to the fibrotic phenotype of
lesional SSc fibroblasts.
The Rac inhibitor NSC23766 reduces the enhanced ability
of lesional SSc fibroblasts to migrate
To assess whether enhanced rac activity may contribute to this
phenomenon, we cultured dermal fibroblasts isolated from SSc
patients and healthy individuals until confluence. A uniform
scratch wound was created across the cell layer, and migration
monitored over 48 hours in the presence or absence of
NSC23766. SSc cells (SScF) migrated faster than control
fibroblasts (NF) (Figure 4). However, incubation of cells with
NSC23766 suppressed the enhanced migratory ability of SSc
fibroblasts to that of controls (Figure 4). Again, rac inhibition had
no appreciable effect on the migration of normal fibroblasts
(Figure 4). Collectively, these data lead additional credence to the
notion that the fibrotic phenotype of lesional SSc fibroblasts is due
to enhanced rac activity.
Rac1 directly promotes a fibrogenic phenotype in
fibroblasts via PI3kinase/Akt
To assess whether activation of rac was sufficient to generate a
fibrogenic phenotype, we transfected into normal fibroblasts (NF)
either an empty expression vector or an expression vector encoding
constitutively active rac1 (NF+empty versus NF+caRac). We then
Figure 1. Rac activity is elevated in dermal fibroblasts cultured from scars of SSc patients. Cells were loaded with or without GTPcS
(positive control, to assess maximal Rac activation) or GDP (as a negative control). Rac-GTP was immunoprecipitated from cell lysates. The
precipitated Rac-GTP was detected by immunoblot analysis using anti-Rac. In parallel, whole cell lysates were subjected to SDS/PAGE and Western
blot analysis with an anti-rac antibody. Quantitative densitometry data is indicated on the right. Lanes are: GTPcS, GDP, cells from three normal
individuals (N1, N2, N3) and three individuals with SSc (SScF1, SScF2, SScF3). Experiments were performed on cells derived from 6 normal individuals
and 6 SSc patients. Quantitative densitometry data is indicated on the right (*=p,0.05 relative to wild-type control).
doi:10.1371/journal.pone.0007438.g001
Rac in Scleroderma
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7438Figure 2. Rac inhibition suppresses the pro-fibrotic phenotype of lesional SSc fibroblasts. mRNA and protein analysis. Fibroblasts
were from normal individuals (NF) and individuals with SSc (SScF) were assessed in the presence or absence of the rac-specific inhibitor (NSC23766,
24 hour treatment 50 mM). (A) Real-time PCR analysis. Messenger RNA was harvested from cells and subjected to real-time PCR analysis to detect the
mRNAs indicated. Fibroblasts from 6 individuals were analyzed. Data represent averages and standard deviation. As a control, 28S RNA was amplified.
Average of three replicates from three separate individuals, adjusted for 28S RNA expression values, are shown (+/2 SD *=p,0.05 significant
inhibition by NSC23766 compared to untreated controls, Student’s paired t test). (B) Western blot analysis. Proteins were harvested and subjected to
Western blot analysis with antibodies directed against the proteins indicated. Densitometry is on the right (+/2 SD, *=p,0.05 significant inhibition
by NSC23766 compared to untreated controls, Student’s paired t test) (C) Immunofluorescence analysis. Cells were fixed and stained with anti-
vinculin antibody to detect focal adhesion and rhodamine phalloidin to detect actin and a-SMA.
doi:10.1371/journal.pone.0007438.g002
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cells 24 hours post-transfection. In parallel, western blot analysis
was performed on extracts prepared from untransfected SSc
fibroblasts (SScF). We found that, compared to empty expression
vector, transfection of an expression vector encoding constitutively
active rac1 into normal fibroblasts resulted in increased production
oftypeIcollagen,a2SMA,CTGFandvinculinprotein(Figure5A).
We then wished to examine the molecular mechanism underlying
the ability of rac1 to promote a fibrogenic phenotype in fibroblasts. To
begin to address this issue, we tested the hypothesis that rac might act
Figure 3. Rac inhibition suppresses the pro-fibrotic phenotype of lesional SSc fibroblasts. Gel contraction analysis. Rac inhibitor
50 mM NSC23766 (24 hour treatment) reduced the ability of lesional SSc fibroblasts to contract a collagen gel matrix: (A) FPCL analysis. The effect of
loss of rac inhibition on the ability of fibroblasts to exert contractiles force in a fixed, tethered floating collagen gel lattice was investigated using a
Culture Force Monitor. Forces generated by fibroblasts were measured over 24 hours; a representative trace is shown (N=3). (B) Floating gel analysis.
The effect of rac inhibition on ECM contraction over 24 hours generated by fibroblasts embedded in a floating collagen gel matrix was evaluated.
Contraction was assessed photographically and by measuring gel weight iameter of contracted gels (n=6; Average +/2 standard deviation is
indicated; *=p,0.05, statistically different from control untreated normal fibroblasts, ANOVA). Note that NSC23766 suppressed the enhanced ECM
contraction by lesional SSc fibroblasts.
doi:10.1371/journal.pone.0007438.g003
Figure 4 Rac inhibition reduces the enhanced migration of lesional SSc fibroblasts. Fibroblasts were subjected to a scratch wound assay in
the presence or absence of 50 mM NSC23766. Cells were cultured on fibronectin until reaching confluence. A uniform linear scrape wound was made
across the cell layer. Three independent experiments were performed Gap size expressed as a percentage of the original wound is shown (average +/2
standard deviation) (*=p,0.05 statistically different relative to untreated healthy controls).
doi:10.1371/journal.pone.0007438.g004
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protein analysis. (A) Transfection of constitutively active rac (ca rac), compared to empty expression vector (empty), increases profibrotic protein
expression. Twenty four hours post-transfection, protein was harvested and subjected to Western blot analysis was conducted with antibodies
detecting the proteins indicated. Average +/2 standard deviation is shown (N=3, *=p,0.05). (B) The effect of rac overexpression is reduced by PI3
kinase inhibition. Cells were transfected with empty expression vector or constitutively active rac (ca rac) in the presence or absence of 100 nM
wortmannin, 10 mM Ly294002, 10 mM U0126 and 10 mM SP600125. Cells were then processed for Western blot analysis as described in (A).
doi:10.1371/journal.pone.0007438.g005
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analysis to assess whether SSc fibroblasts displayed elevated phosphor-
ylation of Akt. Cells were incubated overnight in serum free media in
the presence or absence of NSC23766. Western blot analysis of the
resultant protein whole cell extracts revealed that SSc fibroblasts
possessed elevated phosphorylation of Akt, which was suppressed by
the presence of NSC23766 (Figure 6A, B). Thus SSc fibroblasts
displayed elevated Akt activation in a rac-dependent fashion.
We then investigated if the ability of overexpressed active rac1
to activate profibrotic protein expression in fibroblasts was blocked
by PI3kinase/Akt inhibition. To perform this expreriment, we
repeated our transfection experiments, this time in the presence or
absence of the JNK inhibitor SP600125, the p38 inhibitor
SB203580, the MEK inhibitor U0126 or the PI3 kinase inhibitors
wortmannin and Ly294002. We showed that, of these inhibitors,
only wortmannin and Ly294002 blocked the ability of activated
rac1 to increase profibrotic protein expression indicating that rac1
acted via PI3kinase (Figure 5B).
To extend these data, we showed that overexpression of rac1
could increase the ability of normal fibroblasts to contract a
floating collagen gel matrix, and that this ability was blocked by
wortmannin and Ly294002 but not JNK inhibitor SP600125, the
p38 inhibitor SB203580 or the MEK inhibitor U0126 (Figure 7A).
Finally, previously we had shown that mouse skin fibroblasts
deleted for rac1 were less able to contract a floating collagen gel
matrix relative to control fibroblasts [27]. We confirmed these data
(K/K versus C/C; Figure 7B), and showed that overexpression of
rac1 rescued this phenotype, in a fashion which was sensitive to
wortmannin and Ly294002 (Figure 7B). Collectively, these data
suggest that activated rac can directly promote a fibrogenic
phenotype through PI3kinase/Akt and that targeting rac may be a
viable therapy for fibrosis, including that observed in SSc.
Discussion
Fibrotic diseases are characterized by the persistence of
myofibroblasts within lesions [3–5]. Altered activities of Rho
GTPases, such as Rac, have been proposed to contribute to the
pathology of diseases such as cancer, and, as such, have been
proposed as potential drug targets [35]. Previously, we have
shown, using a conditionally deleted Rac1 allele, that Rac1 is
required for proper cutaneous tissue repair kinetics and for
bleomycin to promote skin fibrosis [26,27]. In these studies, we
showed that Rac1 was required for myofibroblast differentiation
and activity. In this report, we extend these studies and show that a
rac inhibitor reverses the phenotype of lesional fibroblasts isolated
from the skin of scleroderma patients. These results suggest that
anti-Rac strategies may be useful anti-fibrotic treatments. Future
efforts examining the potential utility of rac inhibition as a strategy
in SSc will require an assessment of the specificity of rac inhibition
in selectively blocking fibrogenic responses in vitro and an in vivo
prior to the translation of this knowledge into humans. In this light,
it is important to note that rac is known to mediate a variety of
functions including cytoskeleton organization, transcription, and
cell proliferation in immune, vascular and epithelial systems [38].
Nonetheless, these data support the general notion that targeting
proteins located within cells that are required for myofibroblast
action may be a viable novel anti-fibrotic approach. This novel
approach is required, as strategies blocking extracellular factors
promoting myofibroblast differentiation and fibroblast activation
have not been shown to be effective thus far [39].
Akt (also called protein kinase B, PKB), a serine/threonine
kinase consisting of three members termed PKBa (Akt1), PKBb
(Akt2), and PKBc (Akt3), is activated in cells in response to a
variety of stimuli including hormones, growth factors, and ECM
Figure 6. Akt phosphorylation is elevated in dermal fibroblasts and is reduced by rac inhibition. Whole cell lysates were subjected to
SDS/PAGE and Western blot analysis with an anti-phospho Akt and anti-Akt antibodies in the absence (TOP PANEL) or presence or absence (BOTTOM
PANEL) of 50 mM NSC23766. Quantitative densitometry data is indicated on the right. Experiments were performed on cells derived from 6 normal
individuals and 6 SSc patients. Quantitative densitometry data is indicated on the right (*=p,0.05 relative to wild-type control).
doi:10.1371/journal.pone.0007438.g006
Rac in Scleroderma
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PI3-kinases contribute to a variety of cellular processes including
cell survival, migration cytoskeletal remodeling and metabolic
control [42,43]. Our data showing that Akt was elevated in SSc
cells are consistent with previously published observations from a
different group [44]. However, that rac activity is elevated in SSc
cells and that this is required for enhanced Akt activity in SSc
fibroblasts has not been shown. Moreover, in this current report
we also provided data that rac1-dependent activity was blocked by
PI3kinase/Akt inhibition. Our current results are consistent with
previous observations that endothelin-1 promotes ECM contrac-
tion in fibroblasts via rac and PI3kinase/Akt [34].
In summary, our studies examining the involvement in Rac1 in
dermal function may have profound implications for both
homeostatic and pathological processes by contributing to our
understanding of basic mechanisms regarding wound healing. As a
consequence, our results may have future therapeutic implications
for the treatment of non-healing or chronic skin wounds, and of
fibroproliferative disease.
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